Reuters logo
BRIEF-Amicus Therapeutics sees full-year 2017 net operating cash flow of $175 mln-$200 mln
January 9, 2017 / 12:44 PM / 8 months ago

BRIEF-Amicus Therapeutics sees full-year 2017 net operating cash flow of $175 mln-$200 mln

Jan 9 (Reuters) - Amicus Therapeutics Inc :

* Amicus Therapeutics provides full-year 2017 strategic outlook and financial guidance

* Amicus Therapeutics - additional data from POMPE phase 1/2 clinical study and top-line data from phase 3 epidermolysis bullosa study expected in 2017

* Amicus Therapeutics Inc- company expects full-year 2017 net operating cash flow of between $175 million to $200 million

* Amicus Therapeutics -expects 2017 total net cash spend (including third-party milestone payments, capital expenditures) of between $200 million &$225 million Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below